ArticleCardiovascular diabetology2022

Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.

Yaofu Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.